Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Increased by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC increased its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 42.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 224,409 shares of the biotechnology company's stock after purchasing an additional 66,358 shares during the quarter. Steward Partners Investment Advisory LLC owned 0.20% of Viking Therapeutics worth $9,030,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of VKTX. Blue Trust Inc. grew its position in shares of Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 309 shares during the last quarter. Stone House Investment Management LLC lifted its stake in Viking Therapeutics by 66.7% in the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after buying an additional 200 shares in the last quarter. YANKCOM Partnership acquired a new stake in Viking Therapeutics during the 4th quarter valued at $33,000. S.A. Mason LLC increased its position in Viking Therapeutics by 20.0% during the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock worth $72,000 after buying an additional 300 shares in the last quarter. Finally, Wolff Wiese Magana LLC acquired a new position in shares of Viking Therapeutics in the fourth quarter worth $75,000. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Viking Therapeutics

In other Viking Therapeutics news, COO Marianna Mancini sold 54,215 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the completion of the transaction, the chief operating officer now directly owns 374,134 shares of the company's stock, valued at $15,994,228.50. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Brian Lian sold 194,490 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the completion of the transaction, the chief executive officer now owns 2,366,570 shares of the company's stock, valued at approximately $101,170,867.50. This trade represents a 7.59 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 299,014 shares of company stock worth $12,782,849. 4.70% of the stock is currently owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. William Blair reiterated an "outperform" rating on shares of Viking Therapeutics in a research report on Wednesday, November 20th. Piper Sandler lowered their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a report on Thursday, February 6th. Scotiabank assumed coverage on shares of Viking Therapeutics in a research report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Thursday, February 6th. Finally, Maxim Group cut their price target on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $96.31.

Viking Therapeutics Trading Up 1.5 %

Shares of Viking Therapeutics stock traded up $0.42 during trading hours on Friday, reaching $29.10. The stock had a trading volume of 2,619,863 shares, compared to its average volume of 4,558,312. The firm has a market capitalization of $3.27 billion, a price-to-earnings ratio of -29.10 and a beta of 0.90. Viking Therapeutics, Inc. has a 1 year low of $24.41 and a 1 year high of $89.10. The firm has a 50 day simple moving average of $33.39 and a two-hundred day simple moving average of $49.96.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter last year, the business earned ($0.25) EPS. Sell-side analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.